Ose Immunotherapeutics annual operating income
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics Operating Income Growth & History (OSE)
Ose Immunotherapeutics's operating income was −€37.5M for fiscal 2025.
View full Ose Immunotherapeutics company overviewOse Immunotherapeutics annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€37.5M | −€81.2M | — |
| 2024 | 2024-12-31 | €43.7M | €66.7M | — |
| 2023 | 2023-12-31 | −€23.0M | −€4.5M | — |
| 2022 | 2022-12-31 | −€18.5M | −€1.9M | — |
| 2021 | 2021-12-31 | −€16.6M | €2.4M | — |
| 2020 | 2020-12-31 | −€19.0M | — | — |
Ose Immunotherapeutics operating income trends
Over the last five fiscal years, Ose Immunotherapeutics's operating income decreased from −€19.0M to −€37.5M, a change of −€18.5M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
reported operating income
TickerStat standardizes operating income reported in company official filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ose Immunotherapeutics source filings ↗